Alnylam Q3 2026 net income rises year over year to $2.17 billion
Bitget2026/10/29 12:08- Alnylam Pharmaceuticals’ third-quarter 2026 net income rose to $2.17 billion, including a $1.9 billion income tax benefit.
- Total revenues climbed 17% year over year to $1.46 billion.
- Net product revenues increased 52% year over year to $1.29 billion, primarily driven by increased AMVUTTRA patient demand.
- Target enrollment in nucresiran’s TRITON-CM Phase 3 study expanded to approximately 2,250 patients, with an ATTR-CM launch still expected by 2030.
- Full-year 2026 guidance remained unchanged, including net product revenues of $4.7 billion to $5.1 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-IIFL Finance rallies to a two-month high, boosted by Blackstone deal
The “outlier” in the AI capital expenditure frenzy: Apple (AAPL.US) keeps spending flat, accounting for less than 5% of sales
Apple continues to stand out among major tech peers, largely avoiding the aggressive wave of capital expenditure associated with artificial intelligence (AI) infrastructure.
Youth Employment Declines for 48 Consecutive Months: Behind the Semiconductor Boom, Young South Koreans Are Being Left Behind by the Times
In South Korea, the unemployment rate in October fell to a three-year low of 2.5%. However, the number of employed people decreased by 50,000, youth employment has declined for 48 consecutive months, and domestic demand remains weak.
Crypto prices
More
